759443-19-1Relevant academic research and scientific papers
OGA INHIBITOR COMPOUNDS
-
, (2020/01/11)
The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors of formula (I). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.
2-IMIDAZOLES
-
Page/Page column 9, (2008/12/06)
The present invention relates to compounds of formula I, wherein X is —CH2— or —NH—;Y is —CH(lower alkoxy)-, —CH(lower alkyl)-, —O—, —S—, —S(O)—, —S(O)2— or —CH2—; andAr is phenyl or naphthyl, which rings are optionally substituted by one or two substituents selected from the group consisting of halogen, lower alkoxy, lower alkyl and lower alkyl substituted by halogen;or a pharmaceutically-acceptable acid-addition salt thereof;with the proviso that, when X is —NH—, Y is —CH(lower alkyl)- or —CH2—;and the further proviso that the compound is not2-phenethyl-1H-imidazole hydrochloride,2-(3,4-dichloro-phenoxymethyl)-1H-imidazole hydrochloride,2-(2-chloro-phenoxymethyl)-1H-imidazole hydrochloride,2-(2,3-dichloro-phenoxymethyl)-1H-imidazole,benzyl-(1H-imidazol-2-yl)-amine,(4-chloro-benzyl)-(1H-imidazol-2-yl)-amine, or(2-chloro-benzyl)-(1H-imidazol-2-yl)-amine. The invention relates also to a pharmaceutically-acceptable acid-addition salt of such a compound, processes for making the compound, and a composition comprising such a compound.
